Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, Myasthenia Gravis and Transaminitis: A Case Series and Review
Derrick Ho Wai Siu, Robert Sean O'Neill, Carole A. Harris et al. · Immunotherapy · 2022
Immune checkpoint inhibitors have been incorporated into the treatment of various malignancies. An increasing body of literature is reporting rare but potentially fatal adverse events associated with these agents. In this case series, the authors report the clinical features and outcomes of seven patients who received immune checkpoint inhibitors for different solid organ malignancies and developed a tetrad of immune-related myocarditis, myositis, myasthenia gravis and transaminitis. Herein the authors review the literature and describe the current diagnostic and management approach for this overlapping syndrome. The authors' series highlights the importance of a high index of clinical suspicion, prompt comprehensive investigations, early multidisciplinary team involvement and initiation of immunosuppressive therapy when immune-related adverse events are suspected.
Cited by 10 works. doi:10.2217/imt-2021-0225
Authors
- Derrick Ho Wai Siu
- Robert Sean O'Neill
- Carole A. Harris
- Justine Wang
- Luke Ardolino
- Teesha D. Downton
- Jun Hee Hong
- Venessa T. Chin
- Philip R. Clingan
- Morteza Aghmesheh
- Hussein Soudy
References
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study